Novelix Pharmaceuticals logo

Novelix Pharmaceuticals financials: balance sheet, profit and loss, cash flow

BSE: 536565Healthcare ServicesSmall Cap

NOVELIX PHARMACEUTICALS LIMITED · Face value ₹10 · Listed Oct 2013
Last close ₹68.57down ₹2.62 (3.68%)

Share price at the BSE close on 30 Oct 2026. Previous close ₹71.19.

30 Oct: open ₹71.00, high ₹71.00, low ₹65.65

52-week range of traded prices to 30 Oct 2026
₹49.01Low, 7 Apr 2026₹92.00High, 16 Jun 2026
Market cap
₹195 Cr2,861st largest listed
P/E
53.80
P/B
Shares changed
Dividend yield
Nonein the last 12 months
ROE
11.3%
ROCE
8.7%
Debt to equity
0.09
Volume, BSE
2,391

Novelix Pharmaceuticals' financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Novelix Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
3.50.2Mar 173.10.2Mar 183.60.20Mar 191.00.10Mar 201.0−3.30Mar 21Mar 221.4−0.10Mar 23Mar 24310.10Mar 251322.64.3Mar 26
Peak revenue ₹132 Cr, year to Mar 2026; lowest ₹0.99 Cr, year to Mar 2021A loss in 2 of the 8 years with results on record

Operating and net margin, per cent

  • Operating margin
  • Net margin
9.2%−355.1%5.0%−27.9%−355.1%−36.9%0.5%2.6%4.3%5.8%7.0%9.2%−330.7%−4.3%0.3%1.9%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue132
  2. Materials and goods−127
  3. Employee costs−0.7
  4. Other expenses−1.4
  5. Operating profit3.5
  6. Depreciation−0.1
  7. Other income0.0
  8. One-off items0.0
  9. Finance costs0.0
  10. Profit before tax3.4
  11. Tax−0.8
  12. Net profit2.6

What the company owns

  • Receivables₹59 Cr
  • Plant, investments and other assets₹16 Cr
  • Inventory₹14 Cr
  • Cash and bank₹3 Cr

What pays for it: net worth and liabilities

  • Net worth₹46 Cr
  • Owed to suppliers₹40 Cr
  • Borrowings₹4 Cr
  • Other liabilities₹1 Cr

Profit and loss

Standalone, ₹ crore, years to March. No results on record for the years to Mar 2022 and Mar 2024. The last column is the twelve months to Jun 2026, the latest four quarters added.Novelix Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 MayJun 2026Twelve monthsFiled 13 Aug
Revenue from operations43411–1–31132147
––314–2–31129142
Materials and goods bought–2311–1–30127140
Employee costs––000–0–011
Other expenses––003–0–112
Operating profit before depreciation––00−4–−1–035
Operating margin––5.0%−27.9%−355.1%–−36.9%–0.5%2.6%3.1%
Materials, % of revenue––77.1%73.3%103.1%–96.3%–96.3%95.8%95.2%
Employee costs, % of revenue––9.1%27.4%30.7%–22.2%–0.2%0.5%0.5%
Other expenses, % of revenue––8.7%27.2%321.3%–18.4%–3.0%1.1%1.2%
Depreciation and amortisation00000–0–000
Operating profit after depreciation––00−4–−1–034
Other income00000–1–000
Finance costs––000–0–000
Profit before one-off items and tax0000−3–0–034
One-off items–0000–––000
Profit before tax0000−3–0–034
00000–0–011
Net profit0000−3–0–034
Other comprehensive income––000–––000
Total comprehensive income––00−3–––034
Net margin4.3%5.8%7.0%9.2%−330.7%–−4.3%–0.3%1.9%2.5%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2017 and Mar 2018: the statement does not state its finance costs, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
12.012.18.8–7.2–17.546.5
Share capital8.18.18.1–8.1–10.021.1
Reserves3.94.00.7–−0.9–7.625.4
Borrowings0.00.00.0–0.0–0.04.3
0.20.00.0–0.1–9.741.6
−0.1−0.1−0.1–0.0–0.04.3
Total assets12.112.08.8–7.3–27.292.4
3.34.04.1–3.0–0.33.5
8.88.04.7–4.2–26.988.9
Net debt−0.2−1.0−1.7–−2.8–−0.71.4
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
0.6–0.1–−13.7−22.4
0.6–0.1–−13.7−22.4
4.1–0.6–−13.8−25.9
Receivables4.3–−0.1–−22.6−12.6
Inventories−0.2–−0.3–0.0−13.6
Payables0.0–0.1–8.40.0
Other working capital0.0–0.9–0.40.3
Tax paid0.0–0.0–0.00.0
Capital spending0.0–0.0–0.03.3
Free cash flow0.6–0.1–−13.7−25.6
0.2–0.1–2.9−1.7
Cash from financing0.0–0.0–11.326.4
Dividends paid0.0–0.0–0.00.0
Shares bought back0.0–––0.00.0
Shares issued0.0–0.0––26.4
Net change in cash0.8–0.2–0.62.3
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020. Shares issued is left blank for the year to Mar 2025: the cash-flow statement states money raised on equity instruments other than shares, and with no share capital on record before the period nothing shows whether shares were issued for it, so the figure is not given.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
Earnings per share₹0.19₹0.22₹0.31₹0.12−₹4.04–−₹0.07–₹0.08₹1.21
Diluted earnings per share₹0.19₹0.22₹0.31₹0.12−₹4.04–−₹0.07–––
Book value per share––₹14.83₹14.90₹10.87–₹8.88–₹17.63₹22.05
Shareholder yield––––0.0%–0.0%––−23.7%
Market cap at the year end (₹ crore)66–25–7–26111
Shareholder yield is left blank for the year to Mar 2025: the cash-flow statement states money raised on equity instruments other than shares, and with no share capital on record before the period nothing shows whether shares were issued for it, so the figure is not given.

Ratios

Standalone, years to March.Novelix Pharmaceuticals PE ratio and valuation

RatioMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
Revenue growth−11.3%15.4%−71.3%−4.3%––––330.7%
Operating profit growth––––––––2,288.4%
Net profit growth19.9%38.1%−62.1%–––––2,925.6%
Earnings per share growth15.8%40.9%−61.3%–––––1,412.5%
–2.1%0.8%−31.3%–−0.8%–0.5%8.0%
––−1.3 pts−32.1 pts––––7.5 pts
From the net margin––0.7 pts−29.1 pts––––2.9 pts
From asset turnover––−2.0 pts−3.2 pts––––3.2 pts
From borrowing––0.0 pts0.2 pts––––1.4 pts
Return on capital employed–0.5%−3.0%−40.8%–−8.0%–0.6%6.6%
Cash conversion–––––––−16,194.7%−875.7%
Debt to equity–0.000.000.00–0.00–0.000.09
Receivable days–21780731–50–216163
Inventory days–143889–221–1042
Payable days–1435–––115116
Cash conversion cycle, days–217842115–––11188
Working capital days–8622,4841,085–365–197122
Asset turnover–0.300.090.10–0.19–1.132.21
Assets per rupee of net worth–1.011.001.00–1.01–1.551.87
Sales per rupee of plant–9.743.354.41–8.06–165.4286.94
Capital spending to depreciation–––0.00–0.08–0.0032.21
Plant being built, % of plant in use–0.0%0.0%––––0.0%–
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.3%
Cash from operations against operating profit
−644.7%
Measure5 years3 years
Revenue growth, yearly rate166.3%355.0%
Return on equity, average–4.2%
Return on capital employed, average–3.6%
Operating margin, average–1.5%
Net margin, average–1.1%
Asset turnover, average–1.67
Cash conversion cycle, days, average–100
Debt to equity, average–0.05

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations−22.4
Cash from investing−1.7
Cash from financing26.4
Capital spending3.3
Dividends paid0.0
Shares bought back0.0
Shares issued for cash26.4
Borrowings raised0.0
Borrowings repaid0.0

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2025Mar 2026
Altman Z-scorePublished threshold 1.813.944.09
Beneish M-scorePublished threshold −1.78–6.39
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–44.59
Receivables growth less revenue growthOur threshold 0 percentage points–−105.61
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–1,283.13
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–−3.44
Effective tax ratePublished threshold 17.16 per cent31.4724.90
Tax charged less tax paid, % of profitOur threshold 10 percentage points31.4724.90
A threshold marked as ours has no published figure; it is the line we read the check against.